Matsuura Kentaro, Watanabe Tsunamasa, Iijima Sayuki, Murakami Shuko, Fujiwara Kei, Orito Etsuro, Iio Etsuko, Endo Mio, Kusakabe Atsunori, Shinkai Noboru, Miyaki Tomokatsu, Nojiri Shunsuke, Joh Takashi, Tanaka Yasuhito
Department of Virology, Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Hepatol Res. 2014 Nov;44(12):1208-1216. doi: 10.1111/hepr.12294. Epub 2014 Feb 17.
Several studies have shown that high pretreatment concentrations of serum interferon-γ-inducible protein-10 (IP-10) are correlated with non-response to pegylated interferon (PEG-IFN) plus ribavirin (RBV) for chronic hepatitis C (CHC). However, there are few reports on their effect on the Asian population.
We enrolled 104 Japanese genotype 1 CHC individuals treated with PEG-IFN/RBV and 45 with PEG-IFN/RBV/telaprevir, and evaluated the impact of pretreatment serum IP-10 concentrations on their virological responses.
The pretreatment serum IP-10 concentrations were not correlated with IL28B genotype. The receiver-operator curve analysis determined the cut-off value of IP-10 for predicting a sustained virological response (SVR) as 300 pg/mL. In multivariate analysis, the IL28B favorable genotype and IP-10 concentration of less than 300 pg/mL were independent factors for predicting SVR. In a subgroup of patients with the IL28B favorable genotype, the SVR rate was higher in the patients with IP-10 of less than 300 than in those with 300 pg/mL or more, whereas no patient with the IL28B unfavorable genotype and IP-10 of 300 pg/mL or more achieved SVR. Among the patients treated with PEG-IFN/RBV/telaprevir, low pretreatment concentrations of serum IP-10 were associated with a very rapid virological response, defined as undetectable HCV RNA at week 2 after the start of therapy.
Pretreatment serum IP-10 concentrations are associated with treatment efficacy in PEG-IFN/RBV and with early viral kinetics of hepatitis C virus in PEG-IFN/RBV/telaprevir therapy.
多项研究表明，慢性丙型肝炎（CHC）患者治疗前血清干扰素-γ诱导蛋白10（IP-10）浓度较高与对聚乙二醇干扰素（PEG-IFN）联合利巴韦林（RBV）治疗无反应相关。然而，关于其对亚洲人群影响的报道较少。
我们纳入了104例接受PEG-IFN/RBV治疗的日本基因1型CHC患者和45例接受PEG-IFN/RBV/特拉匹韦治疗的患者，并评估了治疗前血清IP-10浓度对其病毒学反应的影响。
治疗前血清IP-10浓度与IL28B基因型无关。受试者工作特征曲线分析确定预测持续病毒学应答（SVR）的IP-10临界值为300 pg/mL。多因素分析显示，IL28B有利基因型和IP-10浓度低于300 pg/mL是预测SVR的独立因素。在IL28B有利基因型患者亚组中，IP-10低于300 pg/mL的患者SVR率高于IP-10为300 pg/mL或更高的患者，而IL28B不利基因型且IP-10为300 pg/mL或更高的患者无一人实现SVR。在接受PEG-IFN/RBV/特拉匹韦治疗的患者中，治疗前血清IP-10浓度低与非常快速的病毒学应答相关，即治疗开始后第2周检测不到HCV RNA。
治疗前血清IP-10浓度与PEG-IFN/RBV治疗的疗效以及PEG-IFN/RBV/特拉匹韦治疗中丙型肝炎病毒的早期病毒动力学相关。
